Influenza Vaccines Market Growth Driven by Rising Prevalence of Influenza

The influenza vaccines market has seen considerable growth in recent years owing to the rising prevalence of seasonal and pandemic influenza across the globe.

The influenza vaccines market has seen considerable growth in recent years owing to the rising prevalence of seasonal and pandemic influenza across the globe. Influenza, commonly known as flu, is an infectious disease caused by influenza virus with symptoms of fever, cough, sore throat, runny or stuffy nose, body aches, headaches, and tiredness. Influenza vaccines help in building immunity against the influenza virus strains which are expected to cause the most illnesses during upcoming flu seasons. The different types of influenza vaccines include trivalent and quadrivalent influenza vaccines administered through intramuscular injection. These vaccines are important for at-risk groups such as pregnant women, elderly people, and those with chronic medical conditions.

The Global influenza vaccines market is estimated to be valued at US$ 7161.38 Bn in 2024 and is expected to exhibit a CAGR of 33.% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the influenza vaccines Market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.

Key players are focusing on new product launches, agreements, collaborations and geographic expansions to increase their Influenza Vaccines Market Demand share. For instance, in 2023 Sanofi launched its seasonal high-dose quadrivalent influenza vaccine Vaxigrip Tetra indicated for people aged 65 years and older in several countries.

The demand for influenza vaccines is growing significantly owing to increasing awareness about seasonal flu and its prevention, rising immunization coverage for at-risk groups, availability of new influenza vaccine products and variants. According to the World Health Organization (WHO), annual influenza epidemics result in severe illness in millions and up to 650,000 influenza-related deaths globally.

Get More Insights On, Influenza Vaccines Market

Explore More Related Article On, Chemiluminescence Immunoassay Market




Raj Dhote

77 Blog posts

Comments